Vaxart, Inc. (NASDAQ:VXRT) Short Interest Update

Vaxart, Inc. (NASDAQ:VXRT) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 13,280,000 shares, an increase of 17.0% from the February 13th total of 11,350,000 shares. Based on an average daily volume of 1,960,000 shares, the days-to-cover ratio is currently 6.8 days. Approximately 6.0% of the shares of the stock are sold short.

Hedge Funds Weigh In On Vaxart

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its position in shares of Vaxart by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company’s stock worth $1,723,000 after buying an additional 57,911 shares during the last quarter. Silverarc Capital Management LLC lifted its holdings in shares of Vaxart by 7.8% in the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock worth $714,000 after acquiring an additional 77,782 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Vaxart by 95.0% in the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 251,789 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Vaxart in the 4th quarter valued at approximately $129,000. Finally, Bank of America Corp DE grew its holdings in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 17,942 shares during the last quarter. Institutional investors own 18.05% of the company’s stock.

Vaxart Stock Down 2.8 %

VXRT stock opened at $0.57 on Friday. Vaxart has a 52 week low of $0.45 and a 52 week high of $1.41. The business has a 50-day simple moving average of $0.65 and a 200 day simple moving average of $0.71. The company has a market cap of $129.14 million, a PE ratio of -1.38 and a beta of 1.69.

Vaxart (NASDAQ:VXRT) last posted its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. On average, analysts anticipate that Vaxart will post -0.39 EPS for the current fiscal year.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.